JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
16.1.2023 12:00:00 EET | Business Wire | Press release
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 17:00:00 EEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
TestGorilla Survey: Recruiters are Faster with AI, but Not More Confident They’re Finding the Right Candidates19.10.2026 16:00:00 EEST | Press release
AI made finding candidates faster for 72% of US recruiters over the last 12 months, according to TestGorilla's Recruiting in 2026 report, a survey of 1,428 US talent professionals. That speed, however, did not make them any more confident they had found the right person. In fact, of the recruiters that claim AI has made them faster, a third reported no gain in confidence at all, and 18% say their confidence in the match actually fell. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019723138/en/ Recruiters report gains in speed from AI but not in certainty - TestGorilla’s Recruiting in the AI era 2026 report Recruiters are making up the difference themselves, by hand. Of those recruiters, 67% now spend an hour or more manually checking a single candidate before they trust that person can do the job, and nearly 30% spend two hours or more. That is time AI sourcing was supposed to save, not divert to new, extra work. "Recrui
Fortanix Announces Confidential AI for Enterprise Grade Kubernetes Workloads on CNCF® Confidential Containers (CoCo)19.10.2026 16:00:00 EEST | Press release
Fortanix® Inc., a global leader in data and AI security and pioneer of Confidential Computing, today announced support for CNCF Confidential Containers (CoCo) in Fortanix Confidential AI, enabling organizations to run AI workloads on Kubernetes inside hardware-based Trusted Execution Environments (TEEs), on confidential CPUs and GPUs. Enterprises keep the speed and agility of containers while protecting sensitive data, AI models, agents, and applications in use, so they can support their regulatory compliance efforts, scale AI across the business, and adopt frontier AI without compromising data privacy or intellectual property. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019549928/en/ Confidential AI is a critical need in the industry today and a strong ecosystem of industry leaders is collaborating to advance open innovation and help enterprises securely adopt AI at scale. Regulated industries, including financial ser
Lenovo Earns Dual Leader Recognition for IT Sustainability in Latest ISG Provider Lens® Digital Sustainability Reports19.10.2026 16:00:00 EEST | Press release
Lenovo today announced that it has been named a Leader in the IT Solutions quadrant of the 2026 ISG Provider Lens® Digital Sustainability reports for both Europe and the United States, citing the company’s organization-wide approach to IT sustainability, which spans devices, infrastructure and services. The recognition comes as enterprises face the daunting challenge of scaling AI, balancing energy demand, and managing costs and environmental impact as infrastructure needs grow. ISG’s 2026 research estimates the global digital sustainability market to be $34.3 billion—up 12% from 2025. Europe represents 43% of that market, and the U.S. is 33%. Against the backdrop of growing year-over-year demand, Lenovo is broadening its approach to sustainability spanning circular procurement, AI-ready infrastructure, managed lifecycle services and carbon intelligence. Furthermore, Lenovo helps customers consider sustainability throughout the IT lifecycle, from procurement and deployment through oper
Rimini Street to Report Third Quarter 2026 Financial Results on October 29, 202619.10.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 29, 2026. The company will host a conference call and webcast on that date to discuss the third quarter 2026 results and the fourth quarter 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019039553/en/ Rimini Street to Report Third Quarter 2026 Financial Results on October 29, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom